Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.47 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10170261 | 0.98 | HPGD (0.53) | HPGDEPHX1KMT2ARAB9ANPC1 | |
| SCHEMBL12252175 | 0.89 | — | — | |
| SCHEMBL8848512 | 0.84 | EPHX2 (0.55) | HPGDEPHX1KMT2ARAB9ANPC1 | |
| SCHEMBL14817499 | 0.82 | HPGD (0.47) | HPGDEPHX1KMT2ARAB9ANPC1 | |
| SCHEMBL6360164 | 0.82 | EPHX2 (0.53) | HPGDEPHX1KMT2ARAB9ANPC1 | |
| SCHEMBL628952 | 0.81 | KEAP1 (0.57) | HPGDEPHX1KMT2AEPHX2KEAP1 | |
| SCHEMBL8244324 | 0.80 | HPGD (0.53) | HPGDEPHX1KMT2ARAB9ANPC1 | |
| SCHEMBL5645399 | 0.80 | EPHX1 (0.50) | EPHX1KMT2AEPHX2 | |
| SCHEMBL3303333 | 0.80 | HTT (0.43) | HPGDEPHX1KMT2ARAB9ANPC1 | |
| SCHEMBL6607606 | 0.80 | HPGD (0.59) | HPGDEPHX1KMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2021027722-A1 | IMMUNOMODULATOR | 成都先导药物开发股份有限公司 | 2021-02-18 | — | — | WO | disclosed |
| WO-2021027729-A1 | IMMUNOMODULATOR | 成都先导药物开发股份有限公司 | 2021-02-18 | — | — | WO | disclosed |
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELI LILLY AND COMPANY (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2018-09-20 | — | — | US | disclosed |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | HYDRA BIOSCIENCES, INC. | 2013-03-07 | — | — | US | disclosed |
| US-8334378-B2 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | ELI LILLY AND COMPANY | 2012-02-23 | — | — | US | disclosed |
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-7691868-B2 | N-{8-[2-chloro-5-(3-methylamino-prop-1-ynyl)-phenyl]-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl}-acetamide; PI3-kinase modulators for the treatment of inflammatory or allergic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| WO-2010031735-A1 | PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2009-06-04 | — | — | US | disclosed |
| EP-1987019-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
| WO-2007093540-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-6967196-B1 | Sulfonamide compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | QDPR, NQO2, DHPS | HPGD 950/4885EPHX1 1722/4885KMT2A 3009/4885 |
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELANE, CASP3, MMP8 | HPGD 1082/4885EPHX1 330/4885KMT2A 2953/4885 |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | HPGD 1228/4885EPHX1 678/4885KMT2A 4200/4885 |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | HPGD 1082/4885EPHX1 330/4885KMT2A 2953/4885 |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | HPGD 1228/4885EPHX1 678/4885KMT2A 4200/4885 |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | TRPA1, TRPV1, TRPV3 | HPGD 584/4885EPHX1 816/4885KMT2A 3764/4885 |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | HPGD 1082/4885EPHX1 330/4885KMT2A 2953/4885 |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | QDPR, NQO2, CYP3A4 | HPGD 872/4885EPHX1 2458/4885KMT2A 3930/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | HPGD 3617/4885EPHX1 2385/4885KMT2A 754/4885 |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | HPGD 1228/4885EPHX1 678/4885KMT2A 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.